HIV-1整合酶及其抑制剂的研究进展

HIV-1整合酶是由HIV病毒pol基因编码的分子量为32KD的蛋白质,是HIV病毒复制的必需酶之一,它催化病毒DNA整合入宿主染色体DNA。人类细胞中没有HIV 整合酶的类似物[1],理论上抑制整合酶对人体副作用很小。因此HIV-1整合酶成为继HIV-1蛋白酶,逆转录酶后治疗艾滋病的富有吸引力和合理的靶标。本文综述了HIV整合酶结构,抑制剂的研究以及以HIV-1 整和酶为靶点治疗AIDS方法的最新研究进展。     

HIV-1整合酶四聚体结构模拟及其活性位点分析

HIV-1复制需要HIV-1整合酶将其环状DNA整合进宿主DNA中,这其中包括2个重要反应,即“3′-加工”和“链转移”,两者均由HIV-1整合酶催化完成.阻断其中的任一反应,都能达到抑制HIV-1复制的目的.因此,了解HIV-1整合酶的完整结构和聚合状态,对深入探讨其作用机理及设计新型抑制剂具有重要的指导作用.然而,迄今为止仅有HIV-1整合酶单独结构域的晶体结构可供参考,而其全酶晶体结构尚未获得解析.本研究利用分子模拟技术,通过蛋白质 蛋白质/DNA分子对接、动力学模拟等方法,构建了全长整合酶四聚体的结构模型、HIV-1 DNA与整合酶复合物的结构模型,进一步从理论上证实HIV-1整合酶是以四聚体形态发挥催化作用,明确“3′-加工”和“链转移”在HIV-1整合酶上的催化位点.同时,通过与作用机理相似的细菌转座子Tn5转座酶等的结构比对,推测HIV-1整合酶的核心结构域中应有第2个Mg^２＋存在,其位置螯合于Asp64与Glu152之间.在HIV-1整合酶结构研究的基础上,有望进一步设计出新的抗艾滋病药物.     

Sp100与HIV-1整合酶互作并抑制其介导的病毒整合

Sp100是核颗粒ND10的组成蛋白,在哺乳动物细胞中广泛存在．Sp100参与多种细胞生理病理过程,如转录调控、细胞内抗病毒免疫等．利用酵母双杂交系统,我们发现了Sp100的互作蛋白HIV-1整合酶,免疫共沉淀实验进一步证实了Sp100与 HIV-1整合酶的互作,细胞内荧光共定位实验也证实了二者在细胞内部分共定位．此外,突变体实验表明,Sp100的C端300～480氨基酸和HIV-1的催化结构域是两个蛋白质的互作区域．利用siRNA降低细胞内Sp100的表达量,可以增加HIV-1整合酶介导的病毒的整合,反之,细胞内过表达Sp100则会降低HIV-1整合酶介导的病毒的整合．这是首次发现Sp100可以和HIV-1整合酶发生相互作用,并进而抑制病毒的整合．我们发现了Sp100作为HIV-1整合酶互作蛋白的新功能,并扩展了细胞防御病毒感染的相关研究．     

分子信标方法研究HIV-1整合酶3'加工反应动力学

HIV-1整合酶催化病毒cDNA与宿主细胞基因组DNA的整合,是病毒在宿主细胞中增殖的一个关键酶.3'加工是整合酶催化整合过程的第一步反应,3'加工反应动力学的研究对整合酶催化机理研究和以整合酶为靶点的药物研发都具有重要意义.构建了野生型HIV-1整合酶重组质粒,在大肠杆菌BL21中诱导表达,通过对包涵体变性、复性,纯化得到了整合酶蛋白.基于分子信标原理,设计了荧光和淬灭基团标记的DNA底物,通过荧光信号实时监测3'加工反应,对酶反应的动力学性质进行研究.结果表明,纯化的整合酶蛋白具有较高的活性,酶反应表现出显著的Mg2+偏好性.酶动力学研究(Km=131.79 nmol/L,Kcat=0.0042 min-1)表明,该分子信标方法和设计的DNA底物可用于整合酶3'加工反应动力学研究以及酶反应性质的研究.     

分子信标方法研究HIV-1整合酶3'加工反应动力学

HIV-1整合酶催化病毒cDNA与宿主细胞基因组DNA的整合,是病毒在宿主细胞中增殖的一个关键酶。 3'加工是整合酶催化整合过程的第一步反应,3'加工反应动力学的研究对整合酶催化机理研究和以整合酶为靶点的药物研发都具有重要意义。构建了野生型HIV-1整合酶重组质粒,在大肠杆菌BL21中诱导表达,通过对包涵体变性、复性,纯化得到了整合酶蛋白。 基于分子信标原理,设计了荧光和淬灭基团标记的DNA底物,通过荧光信号实时监测3' 加工反应,对酶反应的动力学性质进行研究。 结果表明,纯化的整合酶蛋白具有较高的活性,酶反应表现出显著的Mg²⁺偏好性。 酶动力学研究 (K_m = 131.79 nmol/L,K_cat = 0.0042 min ^-1) 表明,该分子信标方法和设计的DNA底物可用于整合酶3'加工反应动力学研究以及酶反应性质的研究。     

HIV-1整合酶单链抗体的构建及表达

病毒DNA整合到被感染的宿主细胞的染色体上需要逆转录病毒基因组的有效复制,而这一反应是由病毒编码的酶——整合酶(Inte-grase,IN)调节的。由于IN在逆转录病毒生命周期的早期阶段起着关键的作用,所以它已经成了对HIV-1基因治疗的一个非常吸引人的靶蛋白。由于对这个酶缺少有效的抑制剂,人们开始探讨新的抑制其活性的方法,包括抗体的使     

HIV-1整合酶去整合活性高通量检测方法的建立

HIV-1整合酶催化病毒DNA与宿主细胞基因组整合,是病毒复制所需的关键酶之一,也是抗病毒药物研发的重要靶点.IN及其核心结构域均能在体外催化去整合反应.本研究表达纯化了IN和IN-CCD蛋白,建立了一种检测IN和IN-CCD去整合活性的微孔板式高通量方法.设计了生物素和地高辛修饰的去整合DNA底物,运用链亲和素标记的珠子捕获反应产物,再通过酶标地高辛抗体及随后的酶联免疫吸附实验方法对地高辛定量以检测去整合.结果显示,IN和IN-CCD催化的去整合反应信号（A405）分别达到1.6和1.2,而背景信号值低于0.05;IN去整合反应更倾向于使用Mn2＋而不是Mg2＋作为金属辅助离子;研究还发现,已知的IN抑制剂baicalein是IN-CCD抑制剂.以上结果表明,本工作建立的检测方法能高通量、高灵敏度和高特异性地研究去整合反应,并能够应用于以IN为靶点,特别是以IN-CCD为靶点的HIV抑制剂的筛选.     

CDK蛋白在HIV-1复制中的作用研究进展

人类免疫缺陷综合征（Acquired immunodeficiency syndrome,AIDS）是由人免疫缺陷病毒（Human immunodeficiency virus,HIV）感染引起的慢性传染性疾病。HIV根据病毒基因组结构的差异分为HIV-1和HIV-2,而HIV-1是主要的病原体。细胞周期蛋白依赖性激酶（Cyclin dependent kinases,CDKs）在HIV-1复制过程中不可或缺,尤其是在逆转录、转录及病毒RNA加工过程中起到至关重要的作用。本文对CDKs结构、分类及其在HIV-1复制中发挥的作用展开综述,以期为开发针对CDKs靶点的抗HIV-1药物和艾滋病治疗提供线索与思路。     

HIV-1感染诱导丝氨酸/苏氨酸蛋白激酶Citron kinase上调机制研究

HIV-1感染可以改变宿主细胞的表达谱,上调和病毒转录复制翻译包装所需的宿主蛋白,使宿主变成更加适应病毒复制繁殖的环境。研究表明丝氨酸/苏氨酸蛋白激酶Citron kinase(citK)可以促进HIV-1病毒的包装释放,所以我们在本文中进一步探讨了HIV-1感染对Citron kinase在自然生理状态下的表达是否有调节作用。我们用含有荧光素酶报告基因的HIV-1假病毒感染外周血单个核细胞(PBMC)和HEK293T细胞系,检测Citron kinase表达的上调情况。此外,将Citron kinase的上游启动子克隆入含荧光素酶报告基因的载体上,检测HIV假病毒感染对Citron kinase启动子的影响。结果显示:HIV-1可以显著提高PBMC细胞中Citron kinase的表达量,而Citron kinase为HIV-1复制包装所需。在原代CD4+T细胞中过表达Citron kinase,HIV-1的复制可以提高2倍以上。沉默Citron kinase的表达,HIV-1病毒产生量显著降低。在HEK293T细胞系中,HIV-1假病毒感染可以使Citron kinase的mRNA的水平提高2.5倍,蛋白表达量提高2.7倍。我们通过将Citron kinase的启动子克隆到含有荧光素酶报告系统的载体上,感染HIV-1假病毒,发现荧光素酶的活性增加。这提示着HIV-1感染通过转录水平上调Citron kinase的表达,从而为病毒创造复制繁殖更有利的宿主环境。     

以HIV-1 5＇LTR为靶点的药物筛选细胞模型的构建

构建以人类免疫缺陷病毒（HIV-1）5＇LTR为靶点的药物筛选细胞模型,用于体外筛选潜在的对HIV-1启动子具有抑制作用的药物,或用于筛选与HIV-1复制相关的宿主因子。通过PCR扩增HIV-1 5＇LTR片段和胸苷激酶基因（thymidine kinase gene,TK基因）,以这2片段为模板进行重叠PCR将两者连接起来,连接产物经酶切后与pcDNA3.1载体连接;将连接正确的质粒转染HEK293细胞同时用G418加压筛选获得稳定细胞系;加入药物更昔洛韦（GCV）检测TK基因的表达。成功构建了HIV-1 5＇LTR调控TK基因表达的稳定细胞系,在其培养过程中加入药物更昔洛韦时,细胞逐渐死亡。构建了以HIV-1 5＇LTR为靶点的药物筛选细胞模型,该模型利用TK基因作为报告基因方便灵敏,可用于筛选针对HIV-1 5＇LTR的潜在抗HIV药物。     

Assembly of prototype foamy virus strand transfer complexes on product DNA bypassing catalysis of integration

Integrase is the key enzyme that mediates integration of retroviral DNA into cellular DNA which is essential for viral replication. Inhibitors of HIV‐1 that target integrase recognize the nucleoprotein complexes formed by integrase and viral DNA substrate (intasomes) rather than the free enzyme. Atomic resolution structures of HIV‐1 intasomes are therefore required to understand the mechanisms of inhibition and drug resistance. To date, prototype foamy virus (PFV) is the only retrovirus for which such structures have been determined. We show that PFV strand transfer complexes (STC) can be assembled on product DNA without going through the normal forward reaction pathway. The finding that a retroviral STC can be assembled in this way may provide a powerful tool to alleviate the obstacles that impede structural studies of nucleoprotein intermediates in HIV‐1 DNA integration.     

Characterization of Recombinant Integrase of Human Immunodeficiency Virus Type 1 (Isolate Bru)

Integration of the human immunodeficiency virus type 1 (HIV-1) DNA into the human genome requires the virusencoded integrase protein. The recombinant integrase protein of HIV-1 (isolate Bru) was prepared by constructing a plasmid based on pET-15b encoding the integrase gene. Integrase of HIV-1 was purified using a bacterial expression system (Escherichia coli). The main kinetic parameters of HIV-1 integrase (K _m = (3.7 ± 0.2)·10^–10 M, k _cat = (1.2 ± 0.3)·10^–7 sec^–1) were determined using an oligonucleotide duplex constructed on the basis of the U5-terminal sequence of proviral HIV-1 DNA as the substrate. Inhibition of integrase by aurintricarbonic acid ([I]₅₀ = 6.3 ± 0.4 M) and dependence of integrase activity on Mg²⁺ and Mn²⁺ concentration were studied.     

Inhibition of HIV-1 integrase by modified oligonucleotides: Optimization of the inhibitor structure

Integration of human immunodeficiency virus type 1 DNA into the infected cell genome is one of the key steps of the viral replication cycle. Therefore, viral integrase is of interest as a target for new antiviral drugs. Conjugates of 11-mer single-stranded oligonucleotides with hydrophobic molecules were shown to be efficient integrase inhibitors, inducing dissociation of the integrase-viral DNA complex. The dependence of the conjugate inhibitory activity on the oligonucleotide length and structure as well as on the structure of hydrophobic molecules was studied. Conjugates with eosin and oleic acid proved to be the most active. Conjugates of these molecules with 2′-O-methyl-oligonucleotide inhibited integrase at concentrations 50–100 nM but did not influence some other DNA-binding enzymes.     

Outer domains of integrase within retroviral intasomes are dispensible for catalysis of DNA integration

Retroviral DNA integration is mediated by nucleoprotein complexes (intasomes) comprising a pair of viral DNA ends synapsed by a tetramer of integrase. Current integrase inhibitors act on intasomes rather than free integrase protein. Structural and functional studies of intasomes are essential to understand their mechanism of action and how the virus can escape by mutation. To date, prototype foamy virus (PFV) is the only retrovirus for which high‐resolution structures of intasomes have been determined. In the PFV intasome structure, only the core domains of the outer subunits are ordered; the N‐terminal domain, C‐terminal domain, and N‐terminal extension domain are disordered. Are these “missing domains” required for function or are they dispensable? We have devised a strategy to assemble “hetero‐intasomes” in which the outer domains are not present as a tool to assess the functional role of the missing domains for catalysis of integration. We find that the disordered domains of outer subunits are not required for intasome assembly or catalytic activity as catalytic core domains can substitute for the outer subunits in the case of both PFV and HIV‐1 intasomes.     

Molecular dynamics studies of the full-length integrase-DNA complex

We have carried out a molecular dynamics (MD) simulation of full-length HIV-1 integrase (IN) dimer complexed with viral DNA with the aim of gaining information about the enzyme motion and investigating the movement of the catalytic flexible loop (residues 140-149) thought to be essential in the catalytic mechanism of IN. During the simulation, we observed quite a different behavior of this region in the presence or absence of the viral DNA. In particular, the MD results underline the crucial role of the residue Tyr143 in the mechanism of integration of viral DNA into the host chromosome. The present findings confirm the experimental data (e.g., site-directed mutagenesis experiments) showing that the loop is involved in the integration reactions and its mobility is correlated with the catalytic activity of HIV-1 integrase.     

Cellular protein TTRAP interacts with HIV-1 integrase to facilitate viral integration

TTRAP is a PML-NB protein that is involved in the NF-κB signaling pathway. TTRAP was recently identified by yeast two-hybrid analysis as a HIV-1 integrase (HIV-1 IN) interacting protein. This interaction was verified by co-immunoprecipitation, GST pull-down, and intracellular imaging, and deletion assays suggested that the N-terminal 180 residues of TTRAP are responsible for the interaction. In stable TTRAP knock-down cell lines, the integration of viral vectors decreased significantly compared with non-silenced cell lines. Conversely, overexpression of TTRAP by transient transfection increased the percentage of integration events. This is the first time that TTRAP has been shown to interact with HIV-1 IN and facilitate lentiviral vector integration. These findings reveal a new function of TTRAP and expand our understanding of the cellular response to HIV infection. The interaction between TTRAP and HIV-1 IN may be useful in designing new anti-viral strategies as well as for improving the efficiency of lentiviral-vector-mediated gene delivery.     

Structural basis for HIV‐1 DNA integration in the human genome,role of the LEDGF/P75 cofactor

Integration of the human immunodeficiency virus (HIV‐1) cDNA into the human genome is catalysed by integrase. Several studies have shown the importance of the interaction of cellular cofactors with integrase for viral integration and infectivity. In this study, we produced a stable and functional complex between the wild‐type full‐length integrase (IN) and the cellular cofactor LEDGF/p75 that shows enhanced in vitro integration activity compared with the integrase alone. Mass spectrometry analysis and the fitting of known atomic structures in cryo negatively stain electron microscopy (EM) maps revealed that the functional unit comprises two asymmetric integrase dimers and two LEDGF/p75 molecules. In the presence of DNA, EM revealed the DNA‐binding sites and indicated that, in each asymmetric dimer, one integrase molecule performs the catalytic reaction, whereas the other one positions the viral DNA in the active site of the opposite dimer. The positions of the target and viral DNAs for the 3′ processing and integration reaction shed light on the integration mechanism, a process with wide implications for the understanding of viral‐induced pathologies.